| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 418.2 | 610.9 | 540.2 |
| Other income | 24.9 | 51.2 | 22.8 |
| Total income | 443.1 | 662.2 | 563.0 |
| Profit before exceptional items & tax | 144.6 | 276.9 | 186.2 |
| Exceptional items | 0.0 | -1.0 | 0.0 |
| Profit before tax | 144.6 | 277.9 | 186.2 |
| Net profit | 119.9 | 189.8 | 135.8 |
| Operating margin | 32.6% | 42.0% | 33.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -11.70% |
|---|---|
| Net profit, quarter on quarter | -36.80% |
| Revenue, year on year | -22.60% |
| Operating profit, year on year | -15.90% |
| Operating profit, quarter on quarter | -31.50% |
NSE results filing, NSE: ANTHEM. Figures extracted from the filing.
Anthem Biosciences Ltd: key numbers
- Share price
- ₹890.35
- Market cap
- ₹50,144 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 87.1×Sector 47.4×
- Promoter holding
- 71.42%-3.26% QoQ
- FII holding
- 2.57%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anthem Biosciences Ltd
All →Anthem Biosciences Other Announcement
Designated Person Viridity Tone LLP sold shares of Anthem Biosciences Ltd worth ₹82.67 Crore via market sale.
- Value
- ₹82.67 Cr
Anthem Biosciences Legal & Regulatory
Anthem Biosciences Ltd announced the settlement of an upside sharing amount of ₹127.68 Crore related to a prior divestment, following shareholder approval.
- Value
- ₹127.7 Cr
Anthem Biosciences Management Change
Anthem Biosciences appointed S.R. Batliboi & Associates LLP as Statutory Auditor and noted director changes, including a rotation and continuation of directorship.
Anthem Biosciences Annual General Meeting
Anthem Biosciences held its 20th AGM on July 22, 2026. Shareholders approved all business resolutions, including financial statements, dividend declaration, and statutory auditor appointments.
Anthem Biosciences Earnings Call Transcript: Key Takeaways
Revenue fell 25% YoY due to deferred deliveries, though management claims a record order book will drive second-half recovery. While EBITDA margins remain high at 39.6%, the quarter reflects high lumpiness in the CRDMO business.
Anthem Biosciences Results Update
Anthem Biosciences reported Q1FY27 revenue of ₹418.2 Crore and profit after tax of ₹119.9 Crore. The company continues its focus on margin improvement and cost efficiencies.